LAG3 and Parkinson disease: Although a more general pathogenic role for LAG3 in the progression of prion disorders has been ruled out (Liu et al, 2018), impairing the binding of α‐synuclein fibrils to neuronal LAG3 may still constitute an attractive target for small drugs or immunotherapy of PD.